Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Yang Y, Zhang N, Zhang G, Sauve AA
What the Science Recommends The clinical consensus is clear
event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
Hyodo, K., Hashimoto, K., Kuchitsu, K., Suzuki, N
Characterization of mspA, an immunogenic autotransporter protein that mediates adhesion to epithelial and endothelial cells in neisseria meningitidis
PCOS Group: Received subcutaneous injections of DHEA (6 mg/100 g body weight dissolved in 0.2 ml sesame oil) for 21 days to induce PCOS, followed by no additional treatment for 30 days
US$ 27.70
US$ 23.85
US$ 20.11
US$ 20.84
US$ 13714.00
Sold : Login>>
